Abstract
AbstractWe analyzed mutations of 7 vitamin K—dependent protein and cytochrome P450 2C9 genes in 45 patients and investigated whether any contribute to the large interpatient variability in the warfarin dose-effect relationship. Total clearance and daily dose, INR and INR/Cp, were used as pharmacokinetic and pharmacodynamic indexes, respectively. Patients were grouped by genotype based on a single polymorphism and combinations of polymorphisms. Among the 30 sequence variants identified,CYP2C9*3, 165Thr → Metof thefactor IIgene, -402G → A, (37-bp repeat)n, and -746T → Cof thefactor VIIgene, and(CAA repeat)nof the γ-glutamyl carboxylasegene were selected as candidate polymorphisms. As the analysis of single polymorphisms implied, the highest INR/Cp mean values and the lowest warfarin maintenance doses were observed in patients homozygous for the165Met, -402G, (37-bp repeat)6and -746Talleles. Multiple regression analysis revealed that warfarin sensitivity was independently associated with -402G→A, (CAA repeat)n,CYP2C9*3, and165Thr → Met, which accounted for 50% of variance. These results suggest that part of the considerable interpatient variation is attributable to genetic variation, and the combined genotyping ofCYP2C9and certain vitamin K—dependent protein genes is useful for predicting anticoagulant responses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
